Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet. 2021;155(Suppl 1):86–93.
Berkowitz RS, Goldstein DP. Chorionic tumors. N Engl J Med. 1996;335:1740–8.
Ngan HY, Kohorn EI, Cole LA, Kurman RJ, Kim SJ, Lurain JR, et al. Trophoblastic disease. Int J Gynaecol Obstet. 2012;119(Suppl 2):130–6.
Rice LW, Berkowitz RS, Lage JM, Goldstein DP, Bernstein MR. Persistent gestational trophoblastic tumor after partial hydatidiform mole. Gynecol Oncol. 1990;36:358–62.
Feltmate CM, Growdon WB, Wolfberg AJ, Goldstein DP, Genest DR, Chinchilla ME, et al. Clinical characteristics of persistent gestational trophoblastic neoplasia after partial hydatidiform molar pregnancy. J Reprod Med. 2006;51:902–6.
Hancock BW, Nazir K, Everard JE. Persistent gestational trophoblastic neoplasia after partial hydatidiform mole: incidence and outcome. J Reprod Med. 2006;51:764–6.
Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, et al. Gestational trophoblastic neoplasia, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Comper Canc Netw. 2019;17:1374–91.
Goldstein DP, Berkowitz RS, Bernstein MR. Management of molar pregnancy. J Reprod Med. 1981;26:208–12.
Limpongsanurak S. Prophylactic actinomycin D for high-risk complete hydatidiform mole. J Reprod Med. 2001;46:110–6.
Uberti EM, Fajardo MC, Da Cunha AG, Ayub AC, Graudenz MS, Schmid H. Gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high-risk hydatidiform mole: a simple, effective, secure and low-cost approach without adverse effects on compliance to general follow-up or subsequent treatment. Gynecol Oncol. 2009;114:299–305.
Lewis JL, Gore H, Hertig AT, Goss DA. Treatment of trophoblastic neoplasms. With rationale for the use of adjunctive chemotherapy at the time of indicated operation. Am J Obstet Gynecol. 1966;96:710–22.
Wang Q, Fu J, Hu L, Fang F, Xie L, Chen H, et al. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. Cochrane Database Syst Rev. 2017;9:CD007289.
Goldstein DP, Berkowitz RS. Prophylactic chemotherapy of complete molar pregnancy. Semin Oncol. 1995;22:157–60.
Hancock BW. Difference in management and treatment: a critical appraisal. In: Hancock BW, Seckl MJ, Berkowitz RS, Cole LA, editors. Gestational trophoblastic disease. 3rd ed. London: Chapman & Hall Medical; 2009. p. 447–59.
Kim DS, Moon H, Kim KT, Moon YJ, Hwang YY. Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstet Gynecol. 1986;67:690–4.
Seckl M. Time to stop offering prophylactic chemotherapy after molar pregnancies? BJOG. 2014;121:1420.
Soares PD, Maesta I, Costa OL, Charry RC, Dias A, Rudge MV. Geographical distribution and demographic characteristics of gestational trophoblastic disease. J Reprod Med. 2010;55:305–10.
Mangili G, Lorusso D, Brown J, Pfisterer J, Massuger L, Vaughan M, et al. Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer Inter Group. Int J Gynecol Cancer. 2014;24:S109-116.
Charry RC. Presentation and management of molar pregnancy and gestational trophoblastic neoplasia in Latin America. In: Hancock BW, Seckl MJ, Berkowitz RS, Cole LA, editors. Gestational trophoblastic disease. 3rd ed. London: Chapman & Hall Medical; 2009. p. 407–19.
Xiang Y, Qi Z, Xiaohua W, Jihong L, Li L, Miqing Z, et al. Guidelines for the diagnosis and treatment of geatational trophoblastic disease (4th ed). Chin J Pract Gynecol Obstet. 2018;34:994–1001 (in Chinese).
Braga A, Moraes V, Maestá I, Amim Júnior J, Rezende-Filho Jd, Elias K, et al. Changing trends in the clinical presentation and management of complete hydatidiform mole among Brazilian women. Int J Gynecol Cancer. 2016;26:984–90.
Lybol C, Sweep FC, Ottevanger PB, Massuger LF, Thomas CM. Linear regression of postevacuation serum human chorionic gonadotropin concentrations predicts postmolar gestational trophoblastic neoplasia. Int J Gynecol Cancer. 2013;23:1150–6.
Kerkmeijer LG, Massuger LF, Ten Kate-Booij MJ, Sweep FC, Thomas CM. Earlier diagnosis and serum human chorionic gonadotropin regression in complete hydatidiform moles. Obstet Gynecol. 2009;113:326–31.
Kaneki E, Kobayashi H, Hirakawa T, Matsuda T, Kato H, Wake N. Incidence of postmolar gestational trophoblastic disease in androgenetic moles and the morphological features associated with low risk postmolar gestational trophoblastic disease. Cancer Sci. 2010;101:1717–21.
Ngan HYBH, Benedet JL, Jones H, Montruccoli GC, Pecorelli S, FIGO Committee on Gynecologic Oncology. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynecol Cancer. 2003;83(Suppl 1):175–7.
Elias KM, Shoni M, Bernstein M, Goldstein DP, Berkowitz RS. Complete hydatidiform mole in women aged 40–49 years. J Reprod Med. 2012;57:254–8.
Kashimura Y, Kashmira M, Sugimori H, Tsukamoto N, Matsuyama T, Matsukuma K, et al. Prophylactic chemotherapy for hydatidiform mole: 5–15 years follow-up. Cancer. 1986;58:624–9.
Park TK, Kim SN, Lee SK. Analysis of risk factors for postmolar trophoblastic disease: categorization of risk factors and effect of prophylactic chemotherapy. Yonsei Med J. 1966;37:412–9.
Fasoli M, Ratti F, Francheschi S, La Vecchia C, Pecorelli S, Mangioni C. Management of gestational trophoblastic disease: results of a cooperative study. Obstet Gynecol. 1982;60:205–9.
Goldstein DP. Prevention of gestational trophoblastic disease by use of actinomycin D in molar pregnancies. Obstet Gynecol. 1974;43:475–9.
Goldstein DP. Prophylactic chemotherapy of patients with molar pregnancy. Obstet Gynecol. 1971;38:817–22.
Uberti EM, Diestel MC, Guimarães FE, De Nápoli G, Schmid H. Single-dose actinomycin D: efficacy in the prophylaxis of post molar gestational trophoblastic neoplasia in adolescents with high-risk hydatidiform mole. Gynecol Oncol. 2006;102:325–32.
Fowler DJ, Lindsay I, Seckl MJ, Sebire NJ. Routine preevacuation ultrasound diagnosis of hydatidiform mole: experience of more than 1000 cases from a regional referral center. Ultrasound Obst Gyn. 2006;27:56–60.
Koga K, Maeda K. Prophylactic chemotherapy with Amethopterin for prevention of choriocarcinoma following removal of hydatidiform mole. Am J Obstet Gynecol. 1968;100:270–5.
Yamamoto E, Trinh TD, Sekiya Y, Tamakoshi K, Nguyen XP, Nishino K, et al. The management of hydatidiform mole using prophylactic chemotherapy and hysterectomy for high-risk patients decreased the incidence of gestational trophoblastic neoplasia in Vietnam: a retrospective observational study. Nagoya J Med Sci. 2020;82:183–91.